Thermal Laser Treatment in AMD: Therapeutic and Prophylactic

C. Cukras,S. Fine
DOI: https://doi.org/10.1097/IIO.0b013e31802bda65
International Ophthalmology Clinics
Abstract:’ Introduction Age-related macular degeneration (AMD) is the leading cause of severe and irreversible central vision loss in the developed world for people over the age of 55. Although choroidal neovascularization (CNV) may account for less than 10% of all AMD, up to 90% of the severe vision loss seen in AMD is caused by CNV. In the 1970s and 1980s, when laser photocoagulation was first evaluated as treatment for CNV lesions in patients with AMD and related conditions, it was recognized that the natural progression of these lesions had devastating consequences on vision. Several natural history studies, and the trials conducted by the Macular Photocoagulation Study (MPS) Group, documented the visual prognosis of patients with untreated CNV secondary to AMD and ocular histoplasmosis. To compare outcomes of studies conducted during different eras, it is essential to understand how lesions were classified. The MPS defined terms employed subsequently in other large trials including the Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study (TAP). These terms are defined in Table 1. The MPS trials (1979 to 1994) assessed laser treatment for CNV in 3 locations: extrafoveal, juxtafoveal, and subfoveal. In each trial, the control group of untreated eyes provided natural history data. In the initial trial, known as the Senile Macular Degeneration Study, eyes with classic extrafoveal CNV were assigned randomly to immediate argon laser photocoagulation or to observation. Eighteen months after enrollment, 60% of observed eyes versus 25% of laser-treated eyes had lost 6 or more lines of visual acuity. Five years after enrollment, both treated and observed eyes continued to lose vision although the benefit for laser treatment persisted. Within 1 year after enrollment, fluorescein
What problem does this paper attempt to address?